KU-55933
Based on 67 publication(s) in Google Scholar
KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.92%
- CAS No.: 587871-26-9
- Formule: C21H17NO3S2
- Masse moléculaire:395.49
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) KU-55933
More- Cancer Cell. 2021 Apr 12;39(4):566-579.e7. [Abstract]
- Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
- Cell Res. 2026 Mar;36(3):219-232. [Abstract]
- Nat Cell Biol. 2025 Jan;27(1):73-86. [Abstract]
- Drug Resist Updat. 2026 Jan:84:101319. [Abstract]
- Nat Commun. 2025 Jul 15;16(1):6502. [Abstract]
- Nat Commun. 2024 Nov 12;15(1):9515. [Abstract]
- Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
- Mol Cell. 2026 Feb 19;86(4):674-692.e10. [Abstract]
- Mol Cell. 2025 Jul 17;85(14):2654-2672.e7. [Abstract]
- Mol Cell. 2022 Jun 2;82(11):2032-2049.e7. [Abstract]
- Gut Microbes. 2023 Jan-Dec;15(1):2197836. [Abstract]
- Nucleic Acids Res. 2023 Feb 22;51(3):1154-1172. [Abstract]
- Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123. [Abstract]
- J Exp Clin Cancer Res. 2019 Aug 22;38(1):370. [Abstract]
- Adv Sci (Weinh). 2026 Mar;13(13):e15546. [Abstract]
- Sci Adv. 2024 Mar 29;10(13):eadk0564. [Abstract]
- Cell Death Differ. 2022 Dec;29(12):2381-2398. [Abstract]
- Mol Biomed. 2025 Nov 21;6(1):113. [Abstract]
- Cell Death Dis. 2026 Mar 23;17(1):350. [Abstract]
- Cell Mol Biol Lett. 2025 Nov 13;30(1):136. [Abstract]
- Cell Death Dis. 2025 Mar 19;16(1):187. [Abstract]
- Cancer Lett. 2026 May 1:645:218384. [Abstract]
- Cancer Lett. 2024 Apr 1:586:216642. [Abstract]
- Acta Pharmacol Sin. 2025 Dec 1. [Abstract]
- Cell Death Discov. 2024 Mar 11;10(1):130. [Abstract]
- Food Chem. 2022 Jan 30:368:130816. [Abstract]
- Int J Biol Macromol. 2025 May;307(Pt 4):142140. [Abstract]
- Antioxidants (Basel). 2023 Jan 9;12(1):158. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- Environ Pollut. 2026 Apr 1:394:127741. [Abstract]
- Environ Pollut. 2018 Jul:238:1048-1055. [Abstract]
- Cancer Cell Int. 2021 Sep 26;21(1):514. [Abstract]
- Mol Cancer Ther. 2026 Jul 15:10.1158/1535-7163.MCT-26-0182.
- PLoS Biol. 2020 Mar 23;18(3):e3000666. [Abstract]
- J Ethnopharmacol. 2024 Oct 28:333:118430. [Abstract]
- Antioxid Redox Signal. 2021 Oct 10;35(11):849-862. [Abstract]
- Ecotoxicol Environ Saf. 2021 Dec 20:227:112919. [Abstract]
- Ecotoxicol Environ Saf. 2020 Sep 15:201:110831. [Abstract]
- Cell Mol Life Sci. 2024 Oct 12;81(1):432. [Abstract]
- Life Sci. 2021 Mar 15:269:119066. [Abstract]
- J Cell Biol. 2021 Feb 1;220(2):e201911025. [Abstract]
- J Ovarian Res. 2024 Mar 25;17(1):67. [Abstract]
- Chem Biol Interact. 2025 Aug 25:417:111559. [Abstract]
- Mol Med Rep. 2019 Oct;20(4):3661-3670. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- PLoS Pathog. 2025 May 9;21(5):e1013163. [Abstract]
- PLoS Pathog. 2025 Jan 3;21(1):e1012824. [Abstract]
- J Biol Chem. 2026 Jun;302(6):111461. [Abstract]
- J Cell Physiol. 2021 Nov;236(11):7356-7375. [Abstract]
- Vet Res. 2026 Jan 30;57(1):24. [Abstract]
- Toxicol Appl Pharmacol. 2023 Sep 1:474:116625. [Abstract]
- Toxicol Appl Pharmacol. 2022 Jan 15:435:115847. [Abstract]
- Nat Sci Sleep. 2019 Nov 28:11:357-366. [Abstract]
- Front Oncol. 2017 May 19:7:98. [Abstract]
- Biochem Biophys Rep. 2026 Mar 30:46:102568. [Abstract]
- Onco Targets Ther. 2023 Dec 19:16:1061-1071. [Abstract]
- Radiat Res. 2021 May 1;195(5):412-426. [Abstract]
- bioRxiv. 2026 May 21:2026.05.19.726303. [Abstract]
- bioRxiv. 2026 May 26:2026.05.24.727500. [Abstract]
- SSRN. 2026 Mar 5.
- bioRxiv. 2025 Oct 9:2025.10.08.680157. [Abstract]
- Res Sq. 2024 Aug 06.
- Norges teknisk-naturvitenskapelige universitet. 2024.
- bioRxiv. 2024 Mar 29.
- Technische Universitat Darmstadt. 2022 Aug.
- Research Square Preprint. 2021 Nov.
Customer Validation & Images
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
IF
-
WB
-
IP
Activité biologique
Description
IC50 & Target
[1]|
ATM 12.9 nM (IC50) |
DNA-PK 2500 nM (IC50) |
mTOR 9300 nM (IC50) |
PI3K 16600 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
1.8 μM
Compound: 151C
|
Inhibition of DNA-PK in HeLa cell nuclear extracts
Inhibition of DNA-PK in HeLa cell nuclear extracts
|
[PMID: 17371003] |
| HeLa | IC50 |
14 nM
Compound: 42, KU-0055933
|
Inhibition of ATM isolated from human HeLa cell extract using glutathione S-transferase-p53N66 as substrate by ELISA
Inhibition of ATM isolated from human HeLa cell extract using glutathione S-transferase-p53N66 as substrate by ELISA
|
[PMID: 22835870] |
| HT-29 | IC50 |
>30 μM
Compound: 1; KU-55933
|
Inhibition of ATR in human HT-29 cells assessed as reduction in Chk1 phosphorylation at Ser-345 residue after 60 mins in presence of 4-nitroquinoline-1-oxide by Hoechst 33258 staining based plate reader analysis
Inhibition of ATR in human HT-29 cells assessed as reduction in Chk1 phosphorylation at Ser-345 residue after 60 mins in presence of 4-nitroquinoline-1-oxide by Hoechst 33258 staining based plate reader analysis
|
[PMID: 27259031] |
| HT-29 | IC50 |
1.22 μM
Compound: 1; KU-55933
|
Inhibition of ATM phosphorylation at Ser-1981 residue in human HT-29 cells incubated for 1 hr followed by X-ray irradiation by Hoechst staining based fluorescence plate reader analysis
Inhibition of ATM phosphorylation at Ser-1981 residue in human HT-29 cells incubated for 1 hr followed by X-ray irradiation by Hoechst staining based fluorescence plate reader analysis
|
[PMID: 27259031] |
| MCF7 | IC50 |
0.3 μM
Compound: 1; KU55933
|
Inhibition of ATM kinase in human MCF7 cells after 1 hr by immunofluorescence assay
Inhibition of ATM kinase in human MCF7 cells after 1 hr by immunofluorescence assay
|
[PMID: 26632965] |
| MCF7 | IC50 |
24.8 μM
Compound: 1; KU-55933
|
Antiproliferative activity against human MCF7 cells measured after 2 days by SRB assay
Antiproliferative activity against human MCF7 cells measured after 2 days by SRB assay
|
[PMID: 35231830] |
| SW480 | IC50 |
26.5 μM
Compound: 1; KU-55933
|
Antiproliferative activity against human SW480 cells measured after 3 days by SRB assay
Antiproliferative activity against human SW480 cells measured after 3 days by SRB assay
|
[PMID: 35231830] |
| U2OS | IC50 |
250 nM
Compound: 1; KU55933
|
Inhibition of ATM in human U2OS cells assessed as inhibition of p53 phosphorylation at Ser15 residue
Inhibition of ATM in human U2OS cells assessed as inhibition of p53 phosphorylation at Ser15 residue
|
[PMID: 26632965] |
In Vitro
KU-55933 (10 μM) blocks the ionizing radiation-induced p53 serine 15 phosphorylation. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with an estimated IC50 of 300 nM. KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 specifically inhibits ATM but not the other DNA damage-activated PIKKs, ATR, and DNA-PK[1]. KU-55933 induces pATM, p53, E2F1 and pATR, noticeably upregulates the nuclear fraction of E2F1 at the 0.5 h time point[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 587871-26-9
-
Appearance Solid
-
Masse moléculaire 395.49
-
Formule C21H17NO3S2
-
Color White to khaki
-
SMILES
O=C1C=C(OC(C2=C3SC4=C(SC3=CC=C2)C=CC=C4)=C1)N5CCOCC5
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (67)
-
Journal Impact Factor
-
Most Recent
-
Cancer Cell
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. [Abstract]2021 Apr 12;39(4):566-579.e7. PMID: 33848478 -
Cell
Extrachromosomal DNA replication and maintenance couple with DNA damage pathway in tumors. [Abstract]2025 Jun 26;188(13):3405-3421.e27. PMID: 40300601
KU-55933 purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
Representative metaphase FISH images for MYC probes from COLO320DM cells treated with 5 μM KU55933 (ATMi), 0.2 μM AZD7762 (CHKi), and DMSO (no inhibitor) for 24 h. Scale bar, 10 μm.
KU-55933 purchased from MedChemExpress. Usage Cited in: Cell. 2025 Jun 26;188(13):3405-3421.e27. [Abstract]
Dose-response curves showing increased sensitivity to ATMi (KU55933, 0.01-100 μM; 48 h) in ecDNA+ versus ecDNA−cells. Mean values ± SEM are presented.
-
Cell Res
2026 Mar;36(3):219-232. PMID: 41634384 -
Nat Cell Biol
Chromosome mis-segregation triggers cell cycle arrest through a mechanosensitive nuclear envelope checkpoint. [Abstract]2025 Jan;27(1):73-86. PMID: 39779939 -
Drug Resist Updat
ZBP1 antagonizes MRE11-mediated DNA end resection and confers synthetic lethality to PARP inhibition in ovarian cancer. [Abstract]2026 Jan:84:101319. PMID: 41192279 -
Nat Commun
2025 Jul 15;16(1):6502. PMID: 40664653 -
Nat Commun
2024 Nov 12;15(1):9515. PMID: 39532854 -
Nat Commun
Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis. [Abstract]2019 Aug 21;10(1):3761. PMID: 31434880
KU-55933 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761. [Abstract]
IP assays using anti-PRMT5 antibody were performed in indicated cells treated with CPT (10 μM, 1 h) with or without the ATM inhibitor KU55933 (10 μM, 1 h) pretreatment, and IB analysis of the expression of JDP2 and PRMT5.
-
Mol Cell
HSPA1A and DNAJB1 regulate NELF condensate dynamics to safeguard transcriptional recovery under heat stress. [Abstract]2026 Feb 19;86(4):674-692.e10. PMID: 41653920 -
Mol Cell
Lactylation of XLF promotes non-homologous end-joining repair and chemoresistance in cancer. [Abstract]2025 Jul 17;85(14):2654-2672.e7. PMID: 40680721 -
Mol Cell
Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS. [Abstract]2022 Jun 2;82(11):2032-2049.e7. PMID: 35460603
KU-55933 purchased from MedChemExpress. Usage Cited in: Mol Cell. 2022 Jun 2;82(11):2032-2049.e7. [Abstract]
Immunofluoscence assay showing the localization of endogenous PARP1 in HeLa cells left uninfected or infected with HSV-1 at MOI 1 for 4 h in the presence of DMSO, ATR inhibitor VE821 (10 μM), ATM inhibitor KU55933 (10 μM) or DNA-PK inhibitor NU-7026 (10 μM), respectively.
-
Gut Microbes
Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression and chemoresistance by enhancing the secretion of chemotherapy-induced senescence-associated secretory phenotype via activation of DNA damage response pathway. [Abstract]2023 Jan-Dec;15(1):2197836. PMID: 37017266 -
Nucleic Acids Res
Phosphorylation of TRF2 promotes its interaction with TIN2 and regulates DNA damage response at telomeres. [Abstract]2023 Feb 22;51(3):1154-1172. PMID: 36651296 -
Nucleic Acids Res
NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest. [Abstract]2020 Sep 18;48(16):9109-9123. PMID: 32729622
KU-55933 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2020 Sep 18;48(16):9109-9123. [Abstract]
Western blotting of p-ATR, ATR, p-ATM, ATM, p-CHK1, CHK1 and p-CDC2 in A549 cells treated with siCtrl or siNRF2, pretreated with 10 μM VE-821 or 20 μM KU-55933 for 2 h, 5 mM NAC for 1 h, and exposed to 8 Gy Cs137 γ-rays.
-
J Exp Clin Cancer Res
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway. [Abstract]2019 Aug 22;38(1):370. PMID: 31438997 -
Adv Sci (Weinh)
EGR Proteins Mediate Interferon-Independent Anti-HSV-1 Responses Through Viral and Host Targets. [Abstract]2026 Mar;13(13):e15546. PMID: 41486724 -
Sci Adv
2024 Mar 29;10(13):eadk0564. PMID: 38552015 -
Cell Death Differ
BAP1 promotes the repair of UV-induced DNA damage via PARP1-mediated recruitment to damage sites and control of activity and stability. [Abstract]2022 Dec;29(12):2381-2398. PMID: 35637285 -
Mol Biomed
PARP inhibitor BMN673 triggers PARylation-mediated ATF4-GDF15 pathway to drive autophagy and ferroptosis in ataxia telangiectasia mutated gene-deficient colorectal cancer cells. [Abstract]2025 Nov 21;6(1):113. PMID: 41266732 -
Cell Death Dis
2026 Mar 23;17(1):350. PMID: 41872158 -
Cell Mol Biol Lett
E0703 targets ERβ to facilitate the upregulation of GLI3, thereby alleviating irradiation-induced DNA damage on lymphocytes. [Abstract]2025 Nov 13;30(1):136. PMID: 41233737 -
Cell Death Dis
2025 Mar 19;16(1):187. PMID: 40108134 -
Cancer Lett
GPI inactivation mediates pentose phosphate pathway flux switch-on inducing temozolomide resistance in glioma stem cell. [Abstract]2026 May 1:645:218384. PMID: 41763452 -
Cancer Lett
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer. [Abstract]2024 Apr 1:586:216642. PMID: 38278470 -
Acta Pharmacol Sin
ATM promotes bone metastatic propensity of breast cancer by inducing osteoclastogenesis via the NFκB-CCL2 pathway. [Abstract]2025 Dec 1. PMID: 41326811 -
Cell Death Discov
Protein expression of nucleolar protein 12 in the retina and its implication in protection of retina from UV irradiation damage. [Abstract]2024 Mar 11;10(1):130. PMID: 38467618 -
Food Chem
MiR-27a-5p regulates acrylamide-induced mitochondrial dysfunction and intrinsic apoptosis via targeting Btf3 in rats. [Abstract]2022 Jan 30:368:130816. PMID: 34416489 -
Int J Biol Macromol
Combining photodynamic therapy and ATM inhibition using modified bovine serum albumin: A co-delivery nano platform for eliciting pyroptosis and apoptosis to fuel TNBC therapy. [Abstract]2025 May;307(Pt 4):142140. PMID: 40112963 -
Antioxidants (Basel)
Adipose-Derived Mesenchymal Stem Cells Inhibit JNK-Mediated Mitochondrial Retrograde Pathway to Alleviate Acetaminophen-Induced Liver Injury. [Abstract]2023 Jan 9;12(1):158. PMID: 36671020 -
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Environ Pollut
Trichloroethylene induces cardiomyocyte senescence through an AhR-ROS-IL-1 axis and amplified by Wnt/β-catenin suppression. [Abstract]2026 Apr 1:394:127741. PMID: 41643984 -
Environ Pollut
Endosulfan causes the alterations of DNA damage response through ATM-p53 signaling pathway in human leukemia cells. [Abstract]2018 Jul:238:1048-1055. PMID: 29705383
KU-55933 purchased from MedChemExpress. Usage Cited in: Environ Pollut. 2018 Jul:238:1048-1055. [Abstract]
Time-effects of endosulfan on DNA damage and repair related genes. (AeD) Relative mRNA expression levels of ATM (A), BRCA1 (B), BRCA2 (C) and FANCD2 (D) are measured by qRT-PCR after endosulfan exposure (75 μM, for 12, 24 and 48 h) in the absence and presence of KU-55933.
-
Cancer Cell Int
ALDOA inhibits cell cycle arrest induced by DNA damage via the ATM-PLK1 pathway in pancreatic cancer cells. [Abstract]2021 Sep 26;21(1):514. PMID: 34565365 -
-
PLoS Biol
A long noncoding RNA sensitizes genotoxic treatment by attenuating ATM activation and homologous recombination repair in cancers. [Abstract]2020 Mar 23;18(3):e3000666. PMID: 32203529 -
J Ethnopharmacol
Kaempferol from Alpinia officinarum hance induces G2/M cell cycle arrest in hepatocellular carcinoma cells by regulating the ATM/CHEK2/KNL1 pathway. [Abstract]2024 Oct 28:333:118430. PMID: 38857680 -
Antioxid Redox Signal
Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Radiation-Induced Lung Injury via miRNA-214-3p. [Abstract]2021 Oct 10;35(11):849-862. PMID: 32664737 -
Ecotoxicol Environ Saf
The activated ATM/p53 pathway promotes autophagy in response to oxidative stress-mediated DNA damage induced by Microcystin-LR in male germ cells. [Abstract]2021 Dec 20:227:112919. PMID: 34715501 -
Ecotoxicol Environ Saf
Heavy ion radiation-induced DNA damage mediates apoptosis via the Rpl27a-Rpl5-MDM2-p53/E2F1 signaling pathway in mouse spermatogonia. [Abstract]2020 Sep 15:201:110831. PMID: 32535367 -
Cell Mol Life Sci
Long noncoding RNA AK144717 exacerbates pathological cardiac hypertrophy through modulating the cellular distribution of HMGB1 and subsequent DNA damage response. [Abstract]2024 Oct 12;81(1):432. PMID: 39395058 -
Life Sci
Effect of 4,5-diazafluorene derivative on γδ T cell-mediated cytotoxicity against renal cell carcinoma. [Abstract]2021 Mar 15:269:119066. PMID: 33460663 -
J Cell Biol
2021 Feb 1;220(2):e201911025. PMID: 33404607 -
J Ovarian Res
TP63 truncating mutation causes increased cell apoptosis and premature ovarian insufficiency by enhanced transcriptional activation of CLCA2. [Abstract]2024 Mar 25;17(1):67. PMID: 38528613 -
Chem Biol Interact
Acetyl alkannin, a Shikonin monomer, inhibits the ATM/DDR pathway by targeting ATM and sensitizes cisplatin in solid tumors. [Abstract]2025 Aug 25:417:111559. PMID: 40389196 -
Mol Med Rep
CENPO expression regulates gastric cancer cell proliferation and is associated with poor patient prognosis. [Abstract]2019 Oct;20(4):3661-3670. PMID: 31485675 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
PLoS Pathog
SIRT5-mediated desuccinylation of the porcine deltacoronavirus M protein drives pexophagy to enhance viral proliferation. [Abstract]2025 May 9;21(5):e1013163. PMID: 40344161 -
PLoS Pathog
2025 Jan 3;21(1):e1012824. PMID: 39752632 -
J Biol Chem
2026 Jun;302(6):111461. PMID: 41999888 -
J Cell Physiol
NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells. [Abstract]2021 Nov;236(11):7356-7375. PMID: 33982799 -
Vet Res
Activation of the ATM-Chk2 DNA damage response pathway by Newcastle disease virus enhances viral replication. [Abstract]2026 Jan 30;57(1):24. PMID: 41618459 -
Toxicol Appl Pharmacol
Amsacrine downregulates BCL2L1 expression and triggers apoptosis in human chronic myeloid leukemia cells through the SIDT2/NOX4/ERK/HuR pathway. [Abstract]2023 Sep 1:474:116625. PMID: 37451322 -
Toxicol Appl Pharmacol
CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells. [Abstract]2022 Jan 15:435:115847. PMID: 34963561 -
Nat Sci Sleep
Activation of ATM-c-IAP1 Pathway Mediates the Protective Effects of Estradiol in Human Vascular Endothelial Cells Exposed to Intermittent Hypoxia. [Abstract]2019 Nov 28:11:357-366. PMID: 31819689 -
Front Oncol
Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival. [Abstract]2017 May 19:7:98. PMID: 28580318
KU-55933 purchased from MedChemExpress. Usage Cited in: Front Oncol. 2017 May 19:7:98. [Abstract]
ATM inhibition by treatment with KU-55933 (10 µM) strongly reduces HR efficiency in JJN3-HR and U266-HR, although cells are still able to perform HR to some extent.
-
Biochem Biophys Rep
ATM inhibition restores IFN-γ sensitivity and induces ferroptosis in NSCLC via DNA damage response. [Abstract]2026 Mar 30:46:102568. PMID: 41970632 -
Onco Targets Ther
2023 Dec 19:16:1061-1071. PMID: 38144904 -
Radiat Res
Nucleoside Analogs Radiosensitize G0 Cells by Activating DNA End Resection and Alternative End-Joining. [Abstract]2021 May 1;195(5):412-426. PMID: 33755161 -
bioRxiv
Stage-Specific Regulation of DNA Damage Repair by the Circadian Regulator, CRY1, in Prostate Cancer. [Abstract]2026 May 21:2026.05.19.726303. PMID: 42239372 -
bioRxiv
2026 May 26:2026.05.24.727500. PMID: 42244601 -
-
bioRxiv
2025 Oct 9:2025.10.08.680157. PMID: 41279244 -
-
-
-
-
Solvant et solubilité
In Vitro:
DMSO : 50 mg/mL (126.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocole
Kinase Assay[1]
ATM for use in the in vitro assay is obtained by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase-p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37°C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37°C for an additional 1 hour. The plate is centrifuged at 250×g for 10 minutes (4°C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solutionis used to produce a signal and chemiluminescent detection is carried out via a TopCount plate reader.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Assay[1]
1BR or AT4 cells are seeded in 10-cm Petri dishes and treated on day 2 (80 to 90% confluence). Cells are preincubated for 1 hour with KU-55933 or vehicle control and then exposed to 5 Gy of ionizing radiation. Time courses of cell cycle distribution are performed, and the optimal time for discrimination of populations is selected as 16 hours. All subsequent experiments are performed at the 16-hour time point. Cells are stained with propidium iodide according to standard protocols and analyzed by FACS with a FACScalibur. Exponentially growing (50-70% confluent) SW620 cells in 60 mm dishes are exposed to KU-55933 or DMSO for 1 h before addition of etoposide (final concentration of 0.1 and 1 μM) for 16 h before harvesting, propidium iodide staining and analysis as above.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pureté et documentation
-
Fiche technique (284 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Hickson I, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004 Dec 15;64(24):9152-9 [Content Brief]
[2]. Khalil HS, et al. Pharmacological inhibition of ATM by KU55933 stimulates ATM transcription.Exp Biol Med (Maywood). 2012 Jun;237(6):622-34. Epub 2012 Jun 22. [Content Brief]
[3]. Kim YD, et al. Orphan nuclear receptor SHP negatively regulates growth hormone-mediated induction of hepatic gluconeogenesis through inhibition of STAT5 transactivation.J Biol Chem. 2012 Sep 12. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5285 mL | 12.6425 mL | 25.2851 mL | 63.2127 mL |
| 5 mM | 0.5057 mL | 2.5285 mL | 5.0570 mL | 12.6425 mL | |
| 10 mM | 0.2529 mL | 1.2643 mL | 2.5285 mL | 6.3213 mL | |
| 15 mM | 0.1686 mL | 0.8428 mL | 1.6857 mL | 4.2142 mL | |
| 20 mM | 0.1264 mL | 0.6321 mL | 1.2643 mL | 3.1606 mL | |
| 25 mM | 0.1011 mL | 0.5057 mL | 1.0114 mL | 2.5285 mL | |
| 30 mM | 0.0843 mL | 0.4214 mL | 0.8428 mL | 2.1071 mL | |
| 40 mM | 0.0632 mL | 0.3161 mL | 0.6321 mL | 1.5803 mL | |
| 50 mM | 0.0506 mL | 0.2529 mL | 0.5057 mL | 1.2643 mL | |
| 60 mM | 0.0421 mL | 0.2107 mL | 0.4214 mL | 1.0535 mL | |
| 80 mM | 0.0316 mL | 0.1580 mL | 0.3161 mL | 0.7902 mL | |
| 100 mM | 0.0253 mL | 0.1264 mL | 0.2529 mL | 0.6321 mL |
KU-55933 Related Classifications
HY-12016 Related Classifications
Powered by Bioz